Join our daily newsletter At The Bell to receive exclusive market insights
- EMVision (ASX:EMV) reveals the name of its inaugural point-of-care brain scanner device, ’emu’, at the RSNA 2023 conference
- In parallel, the company has fully recruited 150 suspected stroke patients for stage two of its multi-site clinical trial at three leading stroke centres in Australia with results expected in early 2024
- EMV remains on track to commence FDA approvals in early 2024 and continues to collect data which is set to be further enhanced by stage three multi-site trials
- The stage three trial will recruit up to 30 haemorrhagic patients at three sites over the next few months
- EMV shares last traded at $1.57
EMVision Medical Devices (ASX:EMV) has revealed the name of its inaugural point-of-care brain scanner device, ’emu,’ at the Radiological Society of North America (RSNA) 2023 conference.
RSNA serves as a platform to engage with the international clinical community, hosting industry leaders and potential go-to-market partners and customers.
Simultaneously, the company announced the successful recruitment of a cohort comprising 150 suspected stroke patients for stage two of its multi-site clinical trial at three prominent stroke centers in Australia.
The emu device boasts exceptional vision within the human body, emphasising speed, agility, and precision. Utilising electromagnetic technology, it aligns with EMVision’s core proprietary technology.
The pre-validation trial will be conducted at Liverpool Hospital, Royal Melbourne Hospital, and Princess Alexandra Hospital. Upon receiving all relevant data, stage two results are expected to be reported in the first quarter of the 2024 calendar year.
“We are delighted to unveil emu as the brand name for our first-generation product at RSNA, this represents a significant milestone for EMVision and reflects the unique qualities of our product,” EMV CEO and Managing Director Scott Kirkland said.
“Additionally, reaching our target patient recruitment for stage two of the trial is an important step towards our pathway to commercialisation and we are encouraged by the clinical response and data to date.
“We are on track to commence FDA engagement in early 2024 and will continue to collect data in support of the validation phase, further enhanced by Stage 3 of our multi-site trials as planned.”
The stage three trial will recruit up to 30 haemorrhagic patients at the three sites over the next few months.
EMV shares last traded at $1.57.
